PL1750683T3 - Formuły o przedłużonym uwalnianiu - Google Patents

Formuły o przedłużonym uwalnianiu

Info

Publication number
PL1750683T3
PL1750683T3 PL05742315T PL05742315T PL1750683T3 PL 1750683 T3 PL1750683 T3 PL 1750683T3 PL 05742315 T PL05742315 T PL 05742315T PL 05742315 T PL05742315 T PL 05742315T PL 1750683 T3 PL1750683 T3 PL 1750683T3
Authority
PL
Poland
Prior art keywords
sustained release
release formulations
formulations
sustained
release
Prior art date
Application number
PL05742315T
Other languages
English (en)
Polish (pl)
Inventor
Merrill S Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PL1750683T3 publication Critical patent/PL1750683T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05742315T 2004-04-23 2005-04-25 Formuły o przedłużonym uwalnianiu PL1750683T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
EP05742315A EP1750683B1 (en) 2004-04-23 2005-04-25 Sustained release formulations
PCT/US2005/014254 WO2005105057A1 (en) 2004-04-23 2005-04-25 Sustained release formulations

Publications (1)

Publication Number Publication Date
PL1750683T3 true PL1750683T3 (pl) 2013-05-31

Family

ID=34967842

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05742315T PL1750683T3 (pl) 2004-04-23 2005-04-25 Formuły o przedłużonym uwalnianiu

Country Status (15)

Country Link
US (2) US7323169B2 (https=)
EP (1) EP1750683B1 (https=)
JP (3) JP5036533B2 (https=)
KR (1) KR101201638B1 (https=)
CN (2) CN103920162B (https=)
AU (1) AU2005237542B2 (https=)
CA (1) CA2563185C (https=)
DK (1) DK1750683T3 (https=)
ES (1) ES2400687T3 (https=)
IL (1) IL178596A (https=)
PL (1) PL1750683T3 (https=)
PT (1) PT1750683E (https=)
SI (1) SI1750683T1 (https=)
WO (1) WO2005105057A1 (https=)
ZA (1) ZA200609401B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323169B2 (en) * 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
MX2008001468A (es) * 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
AU2007237163A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
MX2009000685A (es) * 2006-07-21 2009-01-30 Amgen Inc Metodo para detectar y/o cuantificar hepcidina en una muestra.
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009105265A2 (en) * 2008-02-21 2009-08-27 Vatrix Medical, Inc. Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
CA2830065A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
US9937255B2 (en) 2011-05-18 2018-04-10 Nectero Medical, Inc. Coated balloons for blood vessel stabilization
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
EP3634507B1 (en) * 2017-06-07 2025-01-15 EGY-Nano Pharma, LP Oral prolonged drug delivery platforms
KR20210068392A (ko) 2018-08-03 2021-06-09 넥테로 메디칼, 인크. 정제된 펜타갈로일 글루코스 및 전달하기 위한 장치
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN119326891B (zh) * 2024-10-31 2025-07-01 中国人民解放军空军军医大学 Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
EP0850051A2 (en) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
KR20010021911A (ko) * 1997-07-23 2001-03-15 추후제출 구강내에서의 약제의 제어방출용 탄닌산-중합체 조성물
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
AU766959B2 (en) * 1998-04-20 2003-10-30 Genzyme Corporation Drug delivery of proteins from polymeric blends
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
AU1360901A (en) 1999-11-01 2001-05-14 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
AU2002254007B2 (en) * 2001-02-22 2006-09-21 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
US20050271603A1 (en) 2002-07-26 2005-12-08 Stephanie Krammer Compositions comprising lactoferrin
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
US7323169B2 (en) * 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations

Also Published As

Publication number Publication date
JP2007534698A (ja) 2007-11-29
EP1750683A1 (en) 2007-02-14
US20070292506A1 (en) 2007-12-20
CN103920162B (zh) 2017-07-11
DK1750683T3 (da) 2013-04-15
JP2012046520A (ja) 2012-03-08
KR20070026457A (ko) 2007-03-08
WO2005105057A1 (en) 2005-11-10
US7323169B2 (en) 2008-01-29
IL178596A (en) 2012-06-28
KR101201638B1 (ko) 2012-11-15
ZA200609401B (en) 2008-05-28
CN1997356A (zh) 2007-07-11
JP5829870B2 (ja) 2015-12-09
AU2005237542B2 (en) 2009-12-17
PT1750683E (pt) 2013-01-25
HK1200092A1 (en) 2015-07-31
CN103920162A (zh) 2014-07-16
AU2005237542A1 (en) 2005-11-10
EP1750683B1 (en) 2013-01-09
ES2400687T3 (es) 2013-04-11
JP2012036194A (ja) 2012-02-23
US7732399B2 (en) 2010-06-08
US20050271722A1 (en) 2005-12-08
CA2563185A1 (en) 2005-11-10
CA2563185C (en) 2010-04-20
SI1750683T1 (sl) 2013-04-30
JP5036533B2 (ja) 2012-09-26
IL178596A0 (en) 2007-02-11
HK1103023A1 (en) 2007-12-14

Similar Documents

Publication Publication Date Title
IL184460A0 (en) Sustained release pharmaeutical formulations
IL178596A0 (en) Sustained release formulations
GB2424581B (en) Formulations
IL181265A0 (en) Stabilizing formulations
GB0406819D0 (en) Controlled release compositions
IL188964A0 (en) Sustained drug release composition
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
ZA200707654B (en) Formulations
HUE053838T2 (hu) Nyújtott felszabadulású nabulfin-készítmények
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1951693A4 (en) SOLID FORMULATIONS
IL177328A0 (en) Controlled release formulations
GB0406048D0 (en) Drug formulations
IL179208A0 (en) Intereferon formulations
GB0417248D0 (en) Formulations
GB0417226D0 (en) Formulations
GB0426292D0 (en) Novel formulations
GB0426296D0 (en) Novel formulations
GB0427249D0 (en) Novel formulations
GB0427248D0 (en) Novel formulations
GB0420817D0 (en) Novel formulations
GB0426293D0 (en) Novel formulations
GB0420821D0 (en) Novel formulations
GB0420820D0 (en) Novel formulations